Literature DB >> 12525270

N-methyl-D-aspartate- enhanced analgesia.

David J Hewitt1.   

Abstract

A greater understanding of the mechanisms that produce chronic pain states has led to a search for novel agents with the potential to produce analgesia by directly modulating specific processes involved in the transduction, transmission, modulation, perception, and encoding of pain. It is hoped that compounds directed at these specific targets will produce better analgesics with an improved side-effect profile. The N-methyl-D-aspartate receptor has been shown to play an important role in pain modulation and has become a target for potential analgesic compounds. Antagonists to the N-methyl-D-aspartate receptor were antinociceptive in a number of animal models, and analgesic in experimental pain models in healthy subjects and in chronic neuropathic pain syndromes. In addition, these compounds have demonstrated the ability to prevent the development of tolerance to opioid analgesic therapy. This has led to investigations of therapies that combine an opioid agonist with an N-methyl-D-aspartate receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525270     DOI: 10.1007/s11916-003-0009-1

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  29 in total

1.  MorphiDex (MS:DM) double-blind, multiple-dose studies in chronic pain patients.

Authors:  N P Katz
Journal:  J Pain Symptom Manage       Date:  2000-01       Impact factor: 3.612

2.  Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo.

Authors:  T Warncke; A Stubhaug; E Jørum
Journal:  Pain       Date:  1997-08       Impact factor: 6.961

3.  The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial.

Authors:  D Pud; E Eisenberg; A Spitzer; R Adler; G Fried; D Yarnitsky
Journal:  Pain       Date:  1998-04       Impact factor: 6.961

4.  Effect of preoperative oral dextromethorphan on immediate and late postoperative pain and hyperalgesia after total abdominal hysterectomy.

Authors:  S Ilkjaer; L F Bach; P A Nielsen; M Wernberg; J B Dahl
Journal:  Pain       Date:  2000-05       Impact factor: 6.961

5.  Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects.

Authors:  Karen M Park; Mitchell B Max; Elaine Robinovitz; Richard H Gracely; Gary J Bennett
Journal:  Pain       Date:  1995-11       Impact factor: 6.961

6.  High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia.

Authors:  K A Nelson; K M Park; E Robinovitz; C Tsigos; M B Max
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

7.  Amantadine, a N-methyl-D-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy.

Authors:  A Gottschalk; F Schroeder; M Ufer; A Oncü; H Buerkle; T Standl
Journal:  Anesth Analg       Date:  2001-07       Impact factor: 5.108

8.  Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo.

Authors:  M B Max; M G Byas-Smith; R H Gracely; G J Bennett
Journal:  Clin Neuropharmacol       Date:  1995-08       Impact factor: 1.592

9.  Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain.

Authors:  S Mercadante; F Lodi; M Sapio; M Calligara; R Serretta
Journal:  J Pain Symptom Manage       Date:  1995-10       Impact factor: 3.612

10.  Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization.

Authors:  Jan Persson; Gudmundur Axelsson; Rolf G Hallin; Lars L Gustafsson
Journal:  Pain       Date:  1995-02       Impact factor: 6.961

View more
  1 in total

1.  In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran.

Authors:  Kazuyoshi Ueta; Takahiro Suzuki; Ichiro Uchida; Takashi Mashimo
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.